Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
70 hedge funds and large institutions have $610M invested in Blueprint Medicines in 2015 Q2 according to their latest regulatory filings, with 70 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRV
Third Rock Ventures
Boston,
Massachusetts
|
+$211M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$116M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$45.2M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$32.6M |
| 5 |
VAM
Visium Asset Management
New York
|
+$27M |
Top Sellers
BPMC Hedge Fund Activity: Q2 2015 in Review
70 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q2 2015, worth a combined $610M.
Buyers outnumbered sellers: 70 funds opened new BPMC positions and 0 closed out — a net gain of 70 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Third Rock Ventures, opening a new position worth an estimated $211M.
- 70 institutional investors held Blueprint Medicines (BPMC) as of Q2 2015, up from 0 in Q1 2015.
- Funds reported $610M of Blueprint Medicines stock for Q2 2015.
- 70 funds opened new Blueprint Medicines positions in Q2 2015 and 0 closed out, a net change of +70 holders.
- The largest Blueprint Medicines buyer in Q2 2015 was Third Rock Ventures, an estimated $211M added.
Based on aggregated 13F filings for Q2 2015.